The lack of AML-specific antigens represents a major barrier, as most targets (e.g., CD33, CD123, CLEC12A) are also expressed on normal hematopoietic stem and progenitor cells (HSPCs), creating a risk of on-target, off-tumor myelotoxicity and prolonged marrow aplasia. Here, CLEC12A is linked to acute myeloid leukemia.